TIDMPXS
RNS Number : 4030N
Provexis PLC
29 January 2021
Prior to publication, the information contained within this
announcement was deemed by the Company to constitute inside
information as stipulated under the UK Market Abuse Regulation.
With the publication of this announcement, this information is now
considered to be in the public domain.
29 January 2021
Provexis plc
UNAUDITED INTERIM RESULTS FOR SIX MONTHS TO 30 SEPTEMBER
2020
Provexis plc ("Provexis" or the "Company"), the business that
develops, licenses and sells the proprietary, scientifically-proven
Fruitflow(R) heart-health functional food ingredient, announces its
unaudited interim results for the six months ended 30 September
2020.
Highlights
-- Total revenue for the period of GBP237k, 7% ahead of the
prior year (2019: GBP222k) and an all-time high in the first half
of the year for the Fruitflow business.
-- Planned launch by By-Health, a circa GBP4bn listed Chinese
dietary supplement business, of a number of Fruitflow based
products in the Chinese market is progressing well. Potential sales
volumes remain at a significant multiple of existing Fruitflow
sales.
-- By-Health has made a significant investment in nine separate
studies in China, at its sole expense, in support of the Fruitflow
based products which it plans to launch in China. Studies conducted
in China are needed to obtain 'blue cap' health claim status for
dietary supplements, as required by the Chinese State
Administration for Market Regulation (SAMR).
-- The five studies which have been completed by By-Health
showed excellent results in use for Fruitflow, and provide strong
evidence for By-Health in its regulatory submissions for Fruitflow.
If a successful blue cap health claim is achieved it would be
expected to result in some significant orders for Fruitflow,
potentially at a multiple of Fruitflow's existing annual sales.
-- Exclusive Distribution Agreement for Fruitflow+ Omega-3 in
China through the Chinese Cross-Border e-commerce channel ('CBEC')
secured in November 2020, first test order has been placed.
-- Company and its commercial partner DSM have experienced
increased consumer interest for Fruitflow in recent months in light
of the COVID-19 pandemic, as consumers look to nutritional
interventions to help them fortify the circulatory system against
the effects of COVID-19.
-- Fruitflow recognised in a further three published scientific
journals, two of them in the context of COVID-19; the Frontiers in
Nutrition journal stated that nutraceuticals such as Fruitflow may
serve as a 'safe antiplatelet prophylactic treatment for those at
high risk of COVID-19.'
-- GBP1.0 million placing completed in December 2019,
significantly strengthening the Company's capital base and
de-risking the business. The funds raised will provide the Company
with additional working capital to support its international growth
plans; a new production run for Fruitflow+ Omega-3 is now in the
process of being commissioned.
-- Purchase of background and joint foreground Oslo blood
pressure lowering IP in August 2020, for a total consideration of
11.5m new ordinary shares in Provexis, giving the Company full
ownership of its four key patent families for Fruitflow.
-- Underlying operating loss* reduced to GBP95k, 24% lower than
the prior year (2019: GBP126k) and a record low for the Group in
the first half of the year.
-- Cash balance of GBP156k at 30 September 2020 (2019: GBP173k).
The Company raised GBP1.0m from a placing in December 2020 with new
and existing investors at 0.75p per new ordinary share.
*before share based payments of GBP107k (2019: GBP39k), as set
out on the face of the Consolidated Statement of Comprehensive
Income.
Provexis Chairman Dawson Buck and CEO Ian Ford commented:
'The Company is pleased to report on another strong period of
progress.
The publication of two review articles for Fruitflow in recent
months focussing on COVID-19, and the publication of a third
article referencing Fruitflow, gut microbiota and their effects on
hypertension and human blood platelet function, represent
significant opportunities for the Company and DSM to promote
Fruitflow further across scientific, trade customer and consumer
channels.
The COVID-19 virus is having a significant adverse effect on
circulation in many patients, and it is causing wider issues with
inflammation. Fruitflow is a natural, breakthrough ingredient that
helps with platelet aggregation, supporting normal blood flow and
circulation. The Company and its commercial partner DSM have
experienced increased consumer interest for Fruitflow in light of
the pandemic, and are seeking to maximise the resulting commercial
opportunities to the benefit of consumers worldwide.
The Company has developed a strong, long lasting and
wide-ranging patent portfolio for Fruitflow, and it holds other
valuable intellectual property and trade secrets for the
technology. The intellectual property for Fruitflow is of
fundamental importance to the Company and its current and future
commercial partners, and the Company was delighted to have secured
outright ownership of the important blood pressure lowering patent
family in August last year. A number of important patents have been
secured for Fruitflow in recent months, as more fully detailed in
this interim report.
The Fruitflow DSM Alliance has made a strong start to the second
half of the 2020/21 financial year, with third quarter revenues to
31 December 2020 expected to be well ahead of the comparative
quarter in 2019/20.
The Company's Fruitflow+ Omega-3 dietary supplement business has
seen continued growth in its subscriber base, with subscriber
numbers on the www.fruitflowplus.com website now standing at a new
all-time high level. The Company is seeking to expand its
commercial activities with Fruitflow+ Omega-3, and a further new
production run for Fruitflow+ Omega-3 capsules is in the process of
being commissioned.
The Company's distribution agreement with a company which will
act as the distributor for Fruitflow+ Omega-3 in China through the
Chinese CBEC channel has made a good start, with a first test order
now having been placed by the distributor and shipped to China.
The planned launch by By-Health, a circa GBP4bn listed Chinese
dietary supplement business, of a number of Fruitflow based
products in the Chinese market is progressing well with potential
sales volumes remaining at a significant multiple of existing
Fruitflow sales. The collaboration agreement which the Company has
with By-Health, in support of By-Health's planned launch of
Fruitflow based products in the Chinese market, further strengthens
the close relationship between By-Health and Provexis.
The Board was delighted to announce a GBP1.0 million placing in
December 2020, with the funds raised helping to provide the Company
with additional working capital to support its international growth
plans. The placing has significantly strengthened the Company's
capital base and de-risked the business to the benefit of all
shareholders.
The Company would like to thank its customers and shareholders
for their continued support, and the Board remains positive about
the outlook for Fruitflow and the Provexis business for the second
half of the financial year and beyond.'
For further information please contact:
Provexis plc Tel: 07490 391888
Ian Ford, CEO enquiries@provexis.com
Dawson Buck, Non-executive Chairman
Allenby Capital Limited (Nominated Tel: 020 3328 5656
Adviser and Broker)
Nick Naylor / Liz Kirchner (Corporate
Finance)
Matt Butlin (Sales and Corporate Broking)
Chairman and CEO's statement
The Company has had a very active first six months of the year,
seeking to enhance further the commercial prospects of its
innovative, patented Fruitflow(R) heart-health ingredient.
The Company's Alliance partner DSM Nutritional Products ('DSM')
has continued to develop the market for Fruitflow in all global
markets. More than 90 regional consumer healthcare brands have now
been launched by direct customers of DSM, and a number of further
regional brands have been launched through DSM's distributor
channels.
The Company and DSM have experienced increased consumer interest
for Fruitflow in recent months in light of the COVID-19 pandemic,
as consumers have looked to nutritional interventions to help them
fortify the circulatory system against the effects of COVID-19. An
increasing number of further commercial projects have been
initiated with prospective customers, including some prospective
customers which are part of global businesses.
The Company continues to work closely with DSM, seeking to
support various prospective customers globally with their
commercialisation plans for Fruitflow, and the total projected
annual sales value of the prospective sales pipeline for Fruitflow
continues to stand at a substantial multiple of existing annual
sales.
Revenues for the half year were GBP237k (2019: GBP222k), an
increase of 7% relative to the prior year.
Underlying operating loss for the half year was reduced to
GBP95k, 24% lower than the prior year (2019: GBP126k) and a record
low for the Group in the first half of the year.
Scientific journal publications
1. In September 2020 Fruitflow was recognised in a review
article by the Frontiers in Nutrition journal
www.frontiersin.org/articles/10.3389/fnut.2020.583080/full which
stated that nutraceuticals such as Fruitflow may serve as:
'A safe antiplatelet prophylactic treatment for those at high
risk of COVID-19 who may also be at increased risk of thrombotic
complications and an alternative to pharmacological compounds that
may cause greater risk of bleeding.'
2. In January 2021 a review article was published by the
influential journal Medical Hypotheses, a leading peer-reviewed
journal which advances new discussion and innovation in medical
treatments.
The article
www.sciencedirect.com/science/article/pii/S0306987720333715, titled
'Platelet hyperactivity in COVID-19: Can the tomato extract
Fruitflow(R) be used as an antiplatelet regime?' was written by
Professor Asim K Duttaroy, who was the original inventor of
Fruitflow, and Dr Niamh O'Kennedy, Provexis plc's Chief Scientific
Officer.
3. In January 2021 a further review article was published in the
MDPI journal Nutrients www.mdpi.com/2072-6643/13/1/144/htm.
The article, titled the 'Role of Gut Microbiota and Their
Metabolites on Atherosclerosis, Hypertension and Human Blood
Platelet Function' was written by Professor Asim K Duttaroy and it
noted that emerging data suggest a strong relationship between
microbiota-derived compounds and an increased risk of CVD, with
widely accumulated data also indicating that Fruitflow may be
useful in the primary prevention of CVD. The article concluded that
there is a 'strong possibility of finding new approaches to treat
or prevent CVD' with further scientific work required seeking to
develop novel preventative or therapeutic regimes.
The publication of these three review articles is a significant
opportunity for the Company and DSM to promote Fruitflow further
across scientific, trade customer and consumer channels.
By-Health Co., Ltd.
The Company has previously announced it was working with DSM and
By-Health Co., Ltd. ('By-Health'), a listed Chinese dietary
supplement business valued at approximately GBP4bn, to support the
planned launch of a number of Fruitflow based products in the
Chinese market.
The planned launch of a number of Fruitflow based products in
the Chinese market, with potential volumes at a significant
multiple of existing Fruitflow sales, is progressing well, with
activities driven at present by the need to obtain 'blue cap'
health claim status for Fruitflow as a dietary supplement with the
State Administration for Market Regulation (SAMR), a new Chinese
market regulator which has taken over the responsibilities of the
former China Food and Drug Administration (CFDA).
Clinical studies conducted in China are typically required to
obtain blue cap health claim status, and a significant investment
in nine separate studies, in support of the Fruitflow based
products which By-Health plans to launch in China, is being
undertaken at By-Health's expense.
Five studies have been successfully completed in China, one
clinical study and one animal study are currently ongoing and a
further planned two human studies have recently been confirmed by
By-Health. The COVID-19 pandemic has caused some delays to the
ongoing and planned studies, with By-Health seeking to keep these
delays to a minimum.
The five completed studies showed excellent results in use for
Fruitflow, and they provide strong evidence for By-Health in its
blue cap and other regulatory submissions to the SAMR for
Fruitflow, supported by the Company's existing European Food Safety
Authority ('EFSA') health claim for Fruitflow.
If a successful blue cap health claim is achieved for Fruitflow
it would currently be expected to result in some significant orders
for the product, potentially at a multiple of current total sales
values. The Company will provide shareholders with as much
information as it can on the timing of this highly commercially
sensitive and potentially transformative process, subject to the
multi-party confidentiality arrangements which surround the
process.
There are more than 230m people in China who are currently
thought to have cardiovascular disease, and a significant increase
in cardiovascular events is expected in China over the course of
the next decade based on population aging and growth alone (source:
World Health Organisation - Cardiovascular diseases, China). China
is now the world's second-largest pharmaceuticals market, measured
by how much patients and the state spend on drugs (source:
health-care information company IQVIA). The Company believes that
Fruitflow has the potential to play an important role in the
Chinese cardiovascular health market.
Fruitflow+ dietary supplement products
Fruitflow+ Omega-3 is available to purchase from the Company's
subscription focussed e-commerce website www.fruitflowplus.com,
Amazon UK and Holland & Barrett.
In November 2020 the Company announced it had entered into a
distribution agreement with a company which is now acting as the
distributor for Fruitflow+ Omega-3 in China, exclusively through
the Chinese Cross-Border e-commerce ('CBEC') channel. A first test
order has been placed by the distributor and shipped to China.
The distribution agreement in China is separate but wholly
complementary to the Company's work with By-Health, with the CBEC
regulations enabling the distributor to sell Fruitflow+ Omega-3 in
China now, prior to the blue cap health claim which By-Health is
seeking to secure.
Fruitflow+ Omega-3 has a social media presence on Facebook
www.facebook.com/FruitflowPlus, Instagram
www.instagram.com/fruitflowplus and Twitter
https://twitter.com/FruitflowPlus, and the Company was pleased to
support Brentford FC in January 2021 as their Emirates FA Cup
Fourth Round tie sleeve sponsor.
The Company believes that Fruitflow has an important role to
play in women's cardiovascular health, and there is a dedicated
section of its consumer website addressing this topic at
www.fruitflowplus.com/womens-health.
A Fruitflow App is also being developed, primarily for use on
mobile device platforms.
Further interest in the role of Fruitflow in exercise has been
generated by pro cycling Team DSM (formerly Team Sunweb)'s use of
Fruitflow in the Tour de France. The benefits that Fruitflow can
provide for athletes in terms of improved recovery are set out in
more detail on the website at
www.fruitflowplus.com/sportrecovery.
The Company continues to work on a potential Fruitflow+ nitrates
product which would be supported by the Company's strong patent
position in this area, with the involvement now of third party
manufacturers and with some interest already generated from brand
owners. The product will have anti-inflammatory and circulation
benefits for athletes seeking to recover after exercise, properties
which would also be potentially beneficial to a wide range of other
consumers to include people who are less active and people who
suffering from the symptoms of basic ageing.
The Company's Fruitflow+ Omega-3 direct selling business has
been operating largely as normal throughout the COVID-19 pandemic,
and despite some initial delays in the supply chain a new
production run of Fruitflow+ Omega-3 capsules was completed in July
2020 thus ensuring continued supply of the product. A further new
production run for Fruitflow+ Omega-3 capsules is in the process of
being commissioned.
Subscriber numbers on the www.fruitflowplus.com website have
been growing steadily, and currently stand at a further new
all-time high level.
The Company is seeking to expand further its commercial
activities with Fruitflow+ Omega-3 and other Fruitflow+ combination
products, and it is currently in dialogue with some other potential
international direct selling customers.
Intellectual property
The Company is responsible for filing and maintaining patents
and trade marks for Fruitflow as part of the Alliance Agreement
with DSM, and patent coverage for Fruitflow now includes the
following patent families:
Patent family Developments in the period from
Sep-20 to Jan-21
Improved Fruitflow / Fruit Extracts
Improved Fruitflow / Fruit Extracts, A second European patent has been
with patents granted by the European secured (previously referred to
Patent Office in January 2017 and as proceeding to grant) and national
September 2020. protection has been secured in
major European states.
The patent has been granted in eight
other major territories to include Patent applications are proceeding
China; patent applications are proceeding to grant in the US, South Korea
to grant in the US and two further and Hong Kong.
territories; and applications are
at a late stage of progression in
a further six global territories,
with potential patent protection
out to November 2029.
--------------------------------------------
Antihypertensive (blood pressure
lowering) effects US patent protection has been secured
This patent was originally developed for Fruitflow as an antihypertensive
in collaboration with the University (blood pressure lowering) agent.
of Oslo, and it has now been granted
for Fruitflow in Europe, the US
and two other major territories.
Patent applications are being progressed
in a further five major territories
to include the US and China, with
potential patent protection out
to April 2033.
In August 2020 the Company announced
it had agreed to purchase the background
and joint foreground blood pressure
lowering IP owned by Inven2 AS,
the technology transfer office at
the University of Oslo, and Provexis
now owns these important patents
outright, with the licensing option
originally held by Inven2 having
been cancelled.
--------------------------------------------
Fruitflow with nitrates in mitigating
exercise-induced inflammation and
for promoting recovery from intense
exercise Patents have been secured (previously
Patents have been granted around referred to as proceeding to grant)
Europe and in the US, Australia, in the US and also Europe, with
Brazil, China, the Philippines, national protection also secured
New Zealand and Japan. Applications in major European states.
have been accepted for grant in Patent protection has also been
Japan (a further patent), South secured in Brazil and patent applications
Korea, Israel and Hong Kong, and are now also proceeding to grant
further patent protection is being in Japan, South Korea, Israel and
sought in seven territories, with Hong Kong.
potential patent protection out
to December 2033.
--------------------------------------------
Fruitflow for air pollution
The use of Fruitflow in protecting US patent protection has been secured
against the adverse effects of air covering the use of Fruitflow in
pollution on the body's cardiovascular protecting subjects who have certain
system. medical conditions and who have
been exposed to air pollution.
Recent laboratory work has shown
that Fruitflow can reduce the platelet
activation caused by airborne particulate
matter, such as that from diesel
emissions, by approximately one
third.
A US application has proceeded to
grant and there are pending applications
in 16 jurisdictions (including the
US where a further application has
been filed) which extends potential
patent protection for Fruitflow
out to November 2037.
--------------------------------------------
Research and development costs for the half year were GBP135k
(2019: GBP134k), reflecting continued investment in the Company's
extensive intellectual property portfolio for Fruitflow, which is
of fundamental importance to the Company and its current and future
commercial partners.
Capital structure and funding
On 17 December 2020 the Group announced it had raised proceeds
of GBP1.0 million via the placing of 133,333,349 ordinary shares of
0.1p each at a gross 0.75p per share with investors, with no
commissions payable. The placing shares were admitted to trading on
AIM on 23 December 2020.
Outlook
The Company is pleased to report on another strong period of
progress.
The publication of two review articles for Fruitflow in recent
months focussing on COVID-19, and the publication of a third
article referencing Fruitflow, gut microbiota and their effects on
hypertension and human blood platelet function, represent
significant opportunities for the Company and DSM to promote
Fruitflow further across scientific, trade customer and consumer
channels.
The COVID-19 virus is having a significant adverse effect on
circulation in many patients, and it is causing wider issues with
inflammation. Fruitflow is a natural, breakthrough ingredient that
helps with platelet aggregation, supporting normal blood flow and
circulation. The Company and its commercial partner DSM have
experienced increased consumer interest for Fruitflow in light of
the pandemic, and are seeking to maximise the resulting commercial
opportunities to the benefit of consumers worldwide.
The Company has developed a strong, long lasting and
wide-ranging patent portfolio for Fruitflow, and it holds other
valuable intellectual property and trade secrets for the
technology. The intellectual property for Fruitflow is of
fundamental importance to the Company and its current and future
commercial partners, and the Company was delighted to have secured
outright ownership of the important blood pressure lowering patent
family in August last year. A number of important patents have been
secured for Fruitflow in recent months, as more fully detailed in
this interim report.
The Fruitflow DSM Alliance has made a strong start to the second
half of the 2020/21 financial year, with third quarter revenues to
31 December 2020 expected to be well ahead of the comparative
quarter in 2019/20.
The Company's Fruitflow+ Omega-3 dietary supplement business has
seen continued growth in its subscriber base, with subscriber
numbers on the www.fruitflowplus.com website now standing at a new
all-time high level. The Company is seeking to expand its
commercial activities with Fruitflow+ Omega-3, and a further new
production run for Fruitflow+ Omega-3 capsules is in the process of
being commissioned.
The Company's distribution agreement with a company which will
act as the distributor for Fruitflow+ Omega-3 in China through the
Chinese CBEC channel has made a good start, with a first test order
now having been placed by the distributor and shipped to China.
The planned launch by By-Health, a circa GBP4bn listed Chinese
dietary supplement business, of a number of Fruitflow based
products in the Chinese market is progressing well with potential
sales volumes remaining at a significant multiple of existing
Fruitflow sales. The collaboration agreement which the Company has
with By-Health, in support of By-Health's planned launch of
Fruitflow based products in the Chinese market, further strengthens
the close relationship between By-Health and Provexis.
The Board was delighted to announce a GBP1.0 million placing in
December 2020, with the funds raised helping to provide the Company
with additional working capital to support its international growth
plans. The placing has significantly strengthened the Company's
capital base and de-risked the business to the benefit of all
shareholders.
The Company would like to thank its customers and shareholders
for their continued support, and the Board remains positive about
the outlook for Fruitflow and the Provexis business for the second
half of the financial year and beyond.
Dawson Buck Ian Ford
Chairman CEO
Consolidated statement of comprehensive
income Unaudited Unaudited Audited
Six months ended 30 September 2020 six months six months year
ended ended ended
30 September 30 September 31 March
2020 2019 2020
GBP GBP GBP
Notes
----------------------------------------- ------ ------------- ------------- ----------
Revenue 237,075 222,262 347,937
Cost of goods (20,728) (19,733) (35,782)
----------------------------------------- ------ ------------- ------------- ----------
Gross profit 216,347 202,529 312,155
Selling and distribution costs (22,956) (19,527) (40,656)
Research and development costs (135,171) (134,078) (251,865)
Administrative costs (including share
based payment charges) (262,104) (223,377) (455,948)
R&D tax relief: receivable tax credit 1,590 8,900 11,502
Underlying operating loss (95,480) (126,155) (320,888)
Share based payment charges - share
options (28,039) (39,398) (103,924)
Share based payment charges - blood
pressure IP (78,775) - -
----------------------------------------- ------ ------------- ------------- ----------
Loss from operations (202,294) (165,553) (424,812)
Finance income 87 155 347
Loss before taxation (202,207) (165,398) (424,465)
Taxation - - -
Loss and total comprehensive expense for
the period (202,207) (165,398) (424,465)
------------------------------------------------- ------------- ------------- ----------
Attributable to:
Owners of the parent (187,832) (150,884) (406,229)
Non-controlling interests (14,375) (14,514) (18,236)
Loss and total comprehensive expense for
the period (202,207) (165,398) (424,465)
------------------------------------------------- ------------- ------------- ----------
Loss per share to owners of the parent
Basic and diluted - pence 3 (0.01) (0.01) (0.02)
----------------------------------------- ------ ------------- ------------- ----------
Consolidated statement of financial
position Unaudited Unaudited Audited
30 September 2020 30 September 30 September 31 March
2020 2019 2020
Notes GBP GBP GBP
------------------------------------- ------- ------------- ------------- -------------
Assets
Current assets
Inventories 80,997 26,132 10,084
Trade and other receivables 142,177 147,327 139,637
Corporation tax asset 13,090 25,100 27,702
Cash and cash equivalents 156,272 173,263 291,335
-------------
Total current assets 392,536 371,822 468,758
---------------------------------------------- ------------- ------------- -------------
Total assets 392,536 371,822 468,758
---------------------------------------------- ------------- ------------- -------------
Liabilities
Current liabilities
Trade and other payables (169,248) (158,934) (150,077)
Total current liabilities (169,248) (158,934) (150,077)
---------------------------------------------- ------------- ------------- -------------
Net current assets 223,288 212,888 318,681
---------------------------------------------- ------------- ------------- -------------
Total liabilities (169,248) (158,934) (150,077)
---------------------------------------------- ------------- ------------- -------------
Total net assets 223,288 212,888 318,681
---------------------------------------------- ------------- ------------- -------------
Capital and reserves attributable
to
owners of the parent company
Share capital 2,070,822 1,983,988 2,059,322
Share premium reserve 17,767,071 17,474,796 17,699,796
Merger reserve 6,599,174 6,599,174 6,599,174
Retained earnings (25,703,718) (25,353,106) (25,543,925)
---------------------------------------------- ------------- ------------- -------------
733,349 704,852 814,367
Non-controlling interest (510,061) (491,964) (495,686)
Total equity 223,288 212,888 318,681
---------------------------------------------- ------------- ------------- -------------
Consolidated statement of cash flows Unaudited Unaudited Audited
30 September 2020 six months six months year
ended ended Ended
30 September 30 September 31 March
2020 2019 2020
GBP GBP GBP
Cash flows from operating activities
Loss after tax (202,207) (165,398) (424,465)
Adjustments for:
Finance income (87) (155) (347)
Tax credit receivable (1,590) (8,900) (11,502)
Share-based payment charge 106,814 39,398 103,924
Changes in inventories (70,913) 19,734 35,782
Changes in trade and other receivables (2,459) (87,585) (80,086)
Changes in trade and other payables 19,171 35,791 26,934
----------
Net cash flow from operations (151,271) (167,115) (349,760)
------------------------------------------- ------------- ------------- ----------
Tax credits received 16,202 14,720 14,720
Total cash flow from operating activities (135,069) (152,395) (335,040)
------------------------------------------- ------------- ------------- ----------
Cash flow from investing activities
Interest received 6 16 399
Total cash flow from investing activities 6 16 399
------------------------------------------- ------------- ------------- ----------
Cash flow from financing activities
Proceeds from issue of share capital - - 300,334
Total cash flow from financing activities - - 300,334
------------------------------------------- ------------- ------------- ----------
Net change in cash and cash equivalents (135,063) (152,379) (34,307)
Opening cash and cash equivalents 291,335 325,642 325,642
Closing cash and cash equivalents 156,272 173,263 291,335
------------------------------------------- ------------- ------------- ----------
Consolidated statement Total
of changes in equity Share Share Merger Retained equity Non- Total
30 September 2020 attributable
to owners controlling
capital premium reserve earnings of interests equity
the parent
GBP GBP GBP GBP GBP GBP GBP
------------------------ ---------- ----------- ---------- ------------- ------------- ------------- ----------
At 31 March 2019 1,983,988 17,474,796 6,599,174 (25,241,620) 816,338 (477,450) 338,888
Share-based charges - - - 39,398 39,398 - 39,398
Total comprehensive
expense for the period - - - (150,884) (150,884) (14,514) (165,398)
At 30 September 2019 1,983,988 17,474,796 6,599,174 (25,353,106) 704,852 (491,964) 212,888
------------------------ ---------- ----------- ---------- ------------- ------------- ------------- ----------
Share-based charges - - - 64,526 64,526 - 64,526
Issue of shares -
placing
17 December 2019 75,334 225,000 - - 300,334 - 300,334
Total comprehensive
expense for the period - - - (255,345) (255,345) (3,722) (259,067)
At 31 March 2020 2,059,322 17,699,796 6,599,174 (25,543,925) 814,367 (495,686) 318,681
------------------------ ---------- ----------- ---------- ------------- ------------- ------------- ----------
Share-based charges -
share options - - - 28,039 28,039 - 28,039
Share-based charges -
blood pressure IP - - - 78,775 78,775 - 78,775
Issue of shares 19
August
2020 - blood pressure
IP 11,500 67,275 - (78,775) - - -
Total comprehensive
expense for the period - - - (187,832) (187,832) (14,375) (202,207)
At 30 September 2020 2,070,822 17,767,071 6,599,174 (25,703,718) 733,349 (510,061) 223,288
------------------------ ---------- ----------- ---------- ------------- ------------- ------------- ----------
1. General information, basis of preparation and accounting
policies
General information
Provexis plc is a public limited company incorporated and
domiciled in the United Kingdom (registration number 05102907). The
address of the registered office is 2 Blagrave Street, Reading,
Berkshire RG1 1AZ, UK.
The main activities of the Group are those of developing,
licensing and selling the proprietary, scientifically-proven
Fruitflow(R) heart-health functional food ingredient.
Basis of preparation
This condensed financial information has been prepared using
accounting policies consistent with International Financial
Reporting Standards in the European Union (IFRS).
The same accounting policies, presentation and methods of
computation are followed in this condensed financial information as
are applied in the Group's latest annual audited financial
statements, except as set out below. While the financial figures
included in this half-yearly report have been computed in
accordance with IFRS applicable to interim periods, this
half-yearly report does not contain sufficient information to
constitute an interim financial report as that term is defined in
IAS 34.
Use of non-GAAP profit measure - underlying operating profit
The directors believe that the operating loss before share based
payments measure provides additional useful information for
shareholders on underlying trends and performance. This measure is
used for internal performance analysis. Underlying operating loss
is not defined by IFRS and therefore may not be directly comparable
with other companies' adjusted profit measures. It is not intended
to be a substitute for, or superior to IFRS measurements of
profit.
The interim financial information does not constitute statutory
accounts as defined in section 434 of the Companies Act 2006 and
has been neither audited nor reviewed by the Company's auditors
James Cowper Kreston pursuant to guidance issued by the Auditing
Practices Board.
The results for the year ended 31 March 2020 are not statutory
accounts. The statutory accounts for the last year ended 31 March
2020 were approved by the Board on 29 September 2020 and are filed
at Companies House. The report of the auditors on those accounts
was unqualified, contained an emphasis of matter with respect to
going concern, and did not contain a statement under section 498 of
the Companies Act 2006.
The interim report for the six months ended 30 September 2020
can be downloaded from the Company's website www.provexis.com.
Further copies of the interim report and copies of the 2020 annual
report and accounts can be obtained by writing to the Company
Secretary, Provexis plc, 2 Blagrave Street, Reading, Berkshire RG1
1AZ, UK.
This announcement was approved by the Board of Provexis plc for
release on 29 January 2021.
Going concern
The Directors are of the opinion that at 29 January 2021, the
Group and Company's liquidity and capital resources are adequate to
deliver the current strategic objectives and 2021 business plan and
that the Group and Company remain a going concern.
Accounting policies
The accounting policies applied are consistent with those of the
annual financial statements for the year ended 31 March 2020, as
described in those annual financial statements.
2. Segmental reporting
The Group's operating segments are determined based on the
Group's internal reporting to the Chief Operating Decision Maker
(CODM). The CODM has been determined to be the Board of Directors
as it is primarily responsible for the allocation of resources to
segments and the assessment of performance of the segments. The
performance of operating segments is assessed on revenue.
The CODM uses revenue as the key measure of the segments'
results as it reflects the segments' underlying trading performance
for the financial period under evaluation. Revenue is reported
separately to the CODM and all other reports are prepared as a
single business unit.
Unaudited Unaudited Audited
six months six months year
ended ended ended
30 September 30 September 31 March
2020 2019 2020
DSM Alliance Agreement 171,976 162,448 232,667
Fruitflow+ Omega-3 56,753 59,814 115,270
Fruitflow+ nitrates - in development 8,346 - -
237,075 222,262 347,937
-------------------------------------- ------------- ------------- ---------
3. Earnings per share
Basic earnings per share amounts are calculated by dividing the
profit attributable to owners of the parent by the weighted average
number of ordinary shares in issue during the period.
The loss attributable to equity holders of the Company for the
purpose of calculating the fully diluted loss per share is
identical to that used for calculating the basic loss per share.
The exercise of share options would have the effect of reducing the
loss per share and is therefore anti-dilutive under the terms of
IAS 33 'Earnings per Share'.
Basic and diluted loss per share amounts are in respect of all
activities.
There were 193,500,000 share options in issue at 30 September
2020 (2019: 193,500,000) that are currently anti-dilutive and have
therefore been excluded from the calculations of the diluted loss
per share.
Unaudited Unaudited Audited
six months six months year
ended ended ended
30 September 30 September 31 March
2020 2019 2020
Loss for the period attributable
to owners of the parent - GBP 187,832 150,884 406,229
Weighted average number of shares 2,061,960,851 1,983,988,174 2,005,600,196
Basic and diluted loss per share
- pence 0.01 0.01 0.02
----------------------------------- -------------- -------------- --------------
On 17 December 2020 the Group announced it had raised proceeds
of GBP1.0 million via the placing of 133,333,349 ordinary shares of
0.1p each at a gross 0.75p per share with investors, with no
commissions payable. The placing shares were admitted to trading on
AIM on 23 December 2020. The new shares issued would change the
weighted average number of shares in issue as shown above for the
period ended 30 September 2020, but they would not significantly
change the resulting loss per share calculations.
4. Share capital and Total Voting Rights
At 29 January 2021, the date of this announcement, the Company's
issued share capital comprises 2,204,154,856 ordinary shares of 0.1
pence each, each with equal voting rights. The Company does not
hold any shares in treasury and therefore the total number of
ordinary shares and voting rights in the Company is
2,204,154,856.
The above figure may be used by shareholders in the Company as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or change to
their interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
5. Cautionary statement
This document contains certain forward-looking statements with
respect to the financial condition, results and operations of the
business. These statements involve risk and uncertainty as they
relate to events and depend on circumstances that will incur in the
future. Nothing in this interim report should be construed as a
profit forecast.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IR PPUAWGUPGGPB
(END) Dow Jones Newswires
January 29, 2021 07:37 ET (12:37 GMT)
Provexis (AQSE:PXS.GB)
Historical Stock Chart
From Jan 2025 to Feb 2025
Provexis (AQSE:PXS.GB)
Historical Stock Chart
From Feb 2024 to Feb 2025
